Research programme : anti-fibrotic therapeutics - ProMetic Life Sciences

Drug Profile

Research programme : anti-fibrotic therapeutics - ProMetic Life Sciences

Alternative Names: PBI-4425; PBI-4547

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ProMetic Life Sciences
  • Class Antifibrotics; Antihyperglycaemics; Small molecules
  • Mechanism of Action Cell differentiation modulators; Collagen inhibitors; Colony stimulating factor stimulants; Cytokine modulators; Erythropoiesis stimulants; Extracellular matrix protein inhibitors; Immunomodulators; Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic nephropathies; Hepatic fibrosis; Idiopathic pulmonary fibrosis; Scleroderma

Most Recent Events

  • 20 Feb 2018 Prometic Life Sciences plans a phase I trial for PBI 4547 for Non-alcoholic steatohepatitis in Q2 2018
  • 20 Feb 2018 ProMetic plans a phase II trial for Liver fibrosis and Metabolic disorders in Q2 2018
  • 14 Aug 2017 PBI 4547, PBI 4425 licensed to Prometic ChinaCo for development in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top